Jump to top menu Jump to main menu Jump to content
Principal Investigator

F.H.W.P. (Floris) Dammeijer, MD, PhD

Principal Investigator

  • Department
  • Pulmonary Medicine
  • Focus area
  • T-cells, antigen-presentation, macrophage-mediated suppression, immunotherapy, solid tumors (incl. lung cancer).

About F.H.W.P. (Floris) Dammeijer, MD, PhD

The majority of patients with cancer do not respond durably to immunotherapy while side-effect are common. As a clinician-scientist (pulmonologist, and basic immunologist) I aim to improve treatments for patients by working from the bench to the bedside, and back. In recent years my group has identified critical mediators and resistance mechanisms to immunotherapy. These include tumor-draining lymph nodes, which we found to be crucial for immunotherapy effectiveness and a source of new targets for future treatment.  

 

My research focuses on elucidating novel mechanisms of resistance to (checkpoint) immunotherapy, and ways to induce immune responses (e.g. through vaccination). Clinically I focus on immunotherapy for (N)SCLC (lung cancer) and mesothelioma. 

My current research lines focus on checkpoint discovery for novel (combination) immunotherapy, how myeloid cells (incl. macrophages, dendritic cells) interact with T cells and how this can be enhanced (focus on lymph nodes and vaccination), and how regulatory T cells (Tregs) are enforced by checkpoint immunotherapy. Key technology we use includes spatial/single-cell transcriptomics, proteomics (incl. flow cytometry), pre-clinical and ex vivo model systems. We strongly collaborate with other groups at the department (e.g. Stadhouders, De Koning), Erasmus MC (Depts of Pathology, Surgery, Medical Oncology) and externally (VIB Gent, LUMC, AUMC, and many others). 

 

I combined my studies in Medicine and Infection & Immunity (Research Master; graduating both cum laude) and continued my career as a scientist (PhD- (cum laude) and post-doc) and pulmonologist-in training (both Erasmus MC). In 2026, I became a pulmonologist, focusing on thoracic oncology and an Assistant Professor/junior PI, studying and targeting immunotherapy resistance. 

Title: The Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Dammeijer et al. 2016, Journal of Clinical Oncology

Title: The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Dammeijer & van Gulijk et al. 2020, Cancer Cell

Title: Immune suppression in the tumor-draining lymph node corresponds with distant disease recurrence in patients with melanoma. Van Krimpen et al. 2022, Cancer Cell

Title: PD-L1 checkpoint blockade promotes regulatory T-cell activity which underlies therapy resistance. Van Gulijk et al. 2023, Science Immunology .

Title: PLA2G2D in tumour-draining lymph nodes regulates anti-tumour immunity. Van Krimpen & Huang et al. 2026, Nature

Alumni PhD-students: 

  • Mandy van Gulijk (2024)

Current PhD-students in the group:

  • Mike Eterman
  • Anneloes van Krimpen
  • Vivian Gerretsen
  • Githa St. Hilaire
  • Chayenne Broens

Postdocs: 

  • Douwe Bosma
  • Declan Whyte

Furthermore:

co-organizer annual Basic & Translational Oncology Course (EMC), co-founder Querido physiology course

Past:

co-chair Hot Topic meeting IASLC 2026 (resistance to immunotherapy in lung cancer) 

 
Basic & Translational Science committee member (IASLC)
  • Nijbakker Morra prize for best MSc thesis in oncology (2015)
  • Young Investigator award (IMIG: mesothelioma research society: 2016)
  • Vera Bonta prize for best PhD thesis in thoracic oncology (NL/BE: 2022)

Main grants: 

  • ZonMw Open competition (co-applicant)
  • ZonMw VENI 
  • KWF Young Investigator Grant